Announced
Completed
Financials
Tags
biotechnology
Biotechnology
United States
Acquisition
Minority
Private
Private Equity
Venture Capital
Completed
Friendly
Single Bidder
Cross Border
Synopsis
A consortium of investors, including Flagship Pioneering, Amgen, NVentures, Mirae Asset Group, Pictet Alternative Advisors, ADIA, Fidelity Management & Research Company, T. Rowe Price, ARCH Venture, Alaska Permanent Fund, Altitude Life Science Ventures, Morningside Ventures and March Capital, led a $273m Series C round in Generate Biomedicines, a biotechnological company focusing on creating breakthrough medicines. “Our Series C round further propels The Generate Platform to increase significantly the precision, speed, and probability of success of novel therapeutics – positioning us to tackle even more complex targets and unmet patient needs. With our first program now in the clinic and multiple programs expected to enter clinical studies over the next couple of years, we are beginning to realize the enormous potential of generative biology to save and improve the lives of patients in areas where the burden of disease is greatest,” Mike Nally, Generate Biomedicines CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.